Regeneron (REGN) and Sanofi (SNY) announced that the FDA has approved Dupixent for the treatment of adult patients with bullous pemphigoid. The FDA approval is based on data from the pivotal ADEPT Phase 2/3 trial that evaluated the efficacy and safety of Dupixent compared to placebo in adults with moderate-to-severe BP.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron Shareholders Approve Key Proposals at 2025 Meeting
- Regeneron’s Promising Blood Thinner Program: Analyst’s Buy Rating Highlights Market Potential
- Regeneron, Sanofi announce Dupixent outperformed Xolair
- 23andMe confirms sale of business to TTAM Research Institute for $305M
- Regeneron: Attractive Valuation and Strong Growth Prospects Justify Buy Rating